TRIUMPH: Preventive Treatment of Migraine Registry: Version (a)
Research type
Research Study
Full title
Protocol I5Q-MC-B004: preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems (TRIUMPH)
IRAS ID
296320
Contact name
Peter Goadsby
Contact email
Sponsor organisation
Lilly UK, Eli Lilly and Company
Duration of Study in the UK
3 years, 9 months, 1 days
Research summary
The overall aim is to estimate real-world effectiveness and associated outcomes, as well as describe treatment patterns, in patients with migraine in routine clinical care who are switching or initiating pharmacologic treatment for migraine prevention. The primary comparison of interest will be between galcanezumab and oral standard of care. However, patients who are initiating other drugs of the same class (calcitonin gene-related peptide receptor antagonists) or botulinum toxin A or B will also be eligible to participate in the study and included in descriptive and statistical comparisons as sample sizes permit.
REC name
East of Scotland Research Ethics Service REC 1
REC reference
21/ES/0049
Date of REC Opinion
17 Jun 2021
REC opinion
Further Information Favourable Opinion